Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 145

Related Citations for PubMed (Select 15044738)

1.

HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs.

Perryman AL, Lin JH, McCammon JA.

Protein Sci. 2004 Apr;13(4):1108-23. Erratum in: Protein Sci. 2004 May;13(5):1434.

3.

Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant.

Todd MJ, Luque I, Velázquez-Campoy A, Freire E.

Biochemistry. 2000 Oct 3;39(39):11876-83.

PMID:
11009599
5.
6.

A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.

Vega S, Kang LW, Velazquez-Campoy A, Kiso Y, Amzel LM, Freire E.

Proteins. 2004 May 15;55(3):594-602.

PMID:
15103623
8.

A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.

Muzammil S, Ross P, Freire E.

Biochemistry. 2003 Jan 28;42(3):631-8.

PMID:
12534275
10.

Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors.

Ala PJ, Huston EE, Klabe RM, McCabe DD, Duke JL, Rizzo CJ, Korant BD, DeLoskey RJ, Lam PY, Hodge CN, Chang CH.

Biochemistry. 1997 Feb 18;36(7):1573-80. Erratum in: Biochemistry 1997 May 27;36(21):6556.

PMID:
9048541
11.
12.

Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations.

Muzammil S, Armstrong AA, Kang LW, Jakalian A, Bonneau PR, Schmelmer V, Amzel LM, Freire E.

J Virol. 2007 May;81(10):5144-54. Epub 2007 Mar 14.

13.

Protein promiscuity: drug resistance and native functions--HIV-1 case.

Fernández A, Tawfik DS, Berkhout B, Sanders R, Kloczkowski A, Sen T, Jernigan B.

J Biomol Struct Dyn. 2005 Jun;22(6):615-24.

PMID:
15842167
14.
15.
16.

Binding of single walled carbon nanotube to WT and mutant HIV-1 proteases: analysis of flap dynamics and binding mechanism.

Meher BR, Wang Y.

J Mol Graph Model. 2012 Sep;38:430-45. doi: 10.1016/j.jmgm.2012.10.001. Epub 2012 Oct 13.

17.

Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design.

Velazquez-Campoy A, Muzammil S, Ohtaka H, Schön A, Vega S, Freire E.

Curr Drug Targets Infect Disord. 2003 Dec;3(4):311-28. Review.

PMID:
14754432
18.

Possible allosteric interactions of monoindazole-substituted P2 cyclic urea analogues with wild-type and mutant HIV-1 protease.

Garg R, Bhhatarai B.

J Comput Aided Mol Des. 2008 Oct;22(10):737-45. doi: 10.1007/s10822-008-9210-y. Epub 2008 Mar 27.

PMID:
18368496
19.
20.

The impact of active site mutations of South African HIV PR on drug resistance: Insight from molecular dynamics simulations, binding free energy and per-residue footprints.

Ahmed SM, Maguire GE, Kruger HG, Govender T.

Chem Biol Drug Des. 2014 Apr;83(4):472-81. doi: 10.1111/cbdd.12262.

PMID:
24267738
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk